Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ascendis Pharma ( (ASND) ) just unveiled an update.
Ascendis Pharma has called its 2026 annual general meeting for March 23, 2026 in Copenhagen, where shareholders will review the company’s activities in 2025, approve the audited annual report and sustainability and P-ESG report for the year ended December 31, 2025, and vote on discharging the board and management from liability. The board will also seek approval to carry forward a consolidated loss of EUR 228 million into accumulated deficit, re-elect the current directors and add industry veteran Jean-Jacques Bienaimé as a new non-executive member, appoint Deloitte as auditor, and extend authority for share buybacks, decisions that shape governance, capital structure flexibility, and oversight for investors ahead of the next phase of the company’s development.
The most recent analyst rating on (ASND) stock is a Buy with a $256.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
Spark’s Take on ASND Stock
According to Spark, TipRanks’ AI Analyst, ASND is a Neutral.
The score is driven primarily by improving fundamentals (rapid revenue growth, strong margins, and a move to positive operating/free cash flow) but is held back by balance-sheet risk (negative equity and high debt) and unprofitable earnings (negative P/E). Technicals are neutral-to-slightly cautious, while the latest earnings call adds support via upbeat guidance and commercial/pipeline momentum despite elevated operating expenses and near-term volatility risks.
To see Spark’s full report on ASND stock, click here.
More about Ascendis Pharma
Ascendis Pharma A/S is a Denmark-based biopharmaceutical company focused on developing and commercializing therapies using its TransCon technology platform. The company targets serious unmet medical needs, with operations and reporting structured under Danish corporate and financial regulation and a global shareholder base via its listed shares and American Depositary Shares.
Average Trading Volume: 706,008
Technical Sentiment Signal: Buy
Current Market Cap: $13.92B
See more insights into ASND stock on TipRanks’ Stock Analysis page.